230 related articles for article (PubMed ID: 17066505)
1. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people.
Kim KK; Cho HJ; Kang HC; Youn BB; Lee KR
Yonsei Med J; 2006 Oct; 47(5):614-25. PubMed ID: 17066505
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity.
Kang JG; Park CY; Kang JH; Park YW; Park SW
Diabetes Obes Metab; 2010 Oct; 12(10):876-82. PubMed ID: 20920040
[TBL] [Abstract][Full Text] [Related]
3. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
Aronne LJ; Halseth AE; Burns CM; Miller S; Shen LZ
Obesity (Silver Spring); 2010 Sep; 18(9):1739-46. PubMed ID: 20094043
[TBL] [Abstract][Full Text] [Related]
4. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
[TBL] [Abstract][Full Text] [Related]
5. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
7. Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial.
Soto-Molina H; Pizarro-Castellanos M; Rosado-Pérez J; Rizzoli-Córdoba A; Lara-Padilla E; del Valle-Laisequilla CF; Reyes-García JG
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):541-9. PubMed ID: 26073353
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
Winslow DH; Bowden CH; DiDonato KP; McCullough PA
Sleep; 2012 Nov; 35(11):1529-39. PubMed ID: 23115402
[TBL] [Abstract][Full Text] [Related]
9. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
Hauner H; Meier M; Wendland G; Kurscheid T; Lauterbach K; ;
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
[TBL] [Abstract][Full Text] [Related]
10. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD
Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346
[TBL] [Abstract][Full Text] [Related]
11. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
12. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
13. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
14. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
15. Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study.
Truant AP; Olon LP; Cobb S
Curr Ther Res Clin Exp; 1972 Nov; 14(11):726-38. PubMed ID: 4629111
[No Abstract] [Full Text] [Related]
16. Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France. Is a combination with topiramate on the horizon?
Prescrire Int; 2012 Sep; 21(130):209. PubMed ID: 23016252
[TBL] [Abstract][Full Text] [Related]
17. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Tronieri JS; Wadden TA; Walsh OA; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Chao AM
Metabolism; 2019 Jul; 96():83-91. PubMed ID: 30902750
[TBL] [Abstract][Full Text] [Related]
18. Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial.
Hollander P; Bays HE; Rosenstock J; Frustaci ME; Fung A; Vercruysse F; Erondu N
Diabetes Care; 2017 May; 40(5):632-639. PubMed ID: 28289041
[TBL] [Abstract][Full Text] [Related]
19. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
[TBL] [Abstract][Full Text] [Related]
20. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.
Cercato C; Roizenblatt VA; Leança CC; Segal A; Lopes Filho AP; Mancini MC; Halpern A
Int J Obes (Lond); 2009 Aug; 33(8):857-65. PubMed ID: 19564877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
